Narayana Hrudayalaya Limited is an India-based healthcare service provider, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The company is primarily engaged in the business of rendering medical and healthcare services. Narayana Hrudayalaya Limited, the flagship company of the Group, was incorporated on **July 19, 2000**, by Dr. Devi Prasad Shetty as its founder.
The company operates as one of India's leading healthcare service providers with a comprehensive network of medical facilities. It manages **19 owned/operated hospitals, 2 heart centers, 18 clinics, and dialysis centers in India**, along with **1 hospital in the Cayman Islands**, totaling **40 healthcare facilities** with **5,789 operational beds** (including Cayman). Overall, the company has a network of 18 hospitals and 2 heart centers across India, along with an overseas presence in the Cayman Islands, boasting over 5,550 operational beds and a capacity of over 5,900 beds.
Narayana Hrudayalaya offers a comprehensive range of medical specialties and services, including:
* Anesthesia, blood bank, bone marrow transplant (stem cell transplant), breast cancer
* Electrophysiology, emergency medicine, endocrinology, family medicine
* Gastrointestinal oncology, general surgery, geriatrics, gynecology - oncology
* Pulmonology, radiation oncology, hematology, heart transplant, hepatology, liver transplantation, and infectious diseases.
Narayana Hrudayalaya Ltd also provides a wide range of primary care services such as preventive health check-ups, nutrition counseling, and health education. The company's top products include **cardiac care, oncology, orthopedic care, and neurosciences**. Its popular brands include **Narayana Health, Narayana Multispecialty Hospital, and Narayana Institute of Cardiac Sciences**.
Narayana Hrudayalaya reported a **3.41% rise in consolidated net profit to ₹197.21 Crore** on an **18.39% increase in revenue from operations to ₹1,475.44 Crore** in Q4 FY25 compared to Q4 FY24. Consolidated total operating revenue was ₹14,754 million for Q4 FY25, reflecting a change of **18.4% YoY and 10.6% QoQ**.
Consolidated EBITDA stood at **₹3,846 million**, reflecting a margin of **26.1%**, as against ₹3,148 million in Q4 FY24, translating into a change of **22.2% YoY and 18.1% QoQ**. Narayana Hrudayalaya reported a **23% YoY increase in EBITDA for Q4 FY25**, driven by strong performance in its Cayman and India operations.
On a full-year basis, the company's net profit rose **0.11% to ₹790.16 Crore** on a **12.12% rise in revenue to ₹5,482.98 Crore** in FY25 over FY24. India's revenue increased **11.3% to ₹4,349.9 Crore** in FY25 against ₹3,908.5 Crore in FY24. Revenue from the Cayman Islands was **₹1,182.9 Crore, up 15.3%**.
* **Revenue Q4 FY25:** ₹1,475.44 Crore
* **Net Profit Q4 FY25:** ₹197.21 Crore
* **Net Profit Margin Q4 FY25:** 13.30%
* **EBITDA Margin Q4 FY25:** 26.1%
* **Annual Revenue FY25:** ₹5,482.98 Crore
* **Annual Net Profit FY25:** ₹790.16 Crore
Narayana Hrudayalaya Ltd has a market capitalization of **₹42,319 Crore**. Promoter holding in Narayana Hrudayalaya Ltd has remained stable at **63.85% as of March 2025** (unchanged from June 2024).
The company's share price has demonstrated strong growth:
* Last 12 Months: Narayana Hrudayalaya Ltd share price moved up by **73.29% on BSE**.
* Last 3 Years: Narayana Hrudayalaya Ltd share price moved up by **225.94% on BSE**.
* **63.64% of analysts recommend a 'BUY' rating** for Narayana Hrudayalaya Ltd.
The board has recommended a **final dividend of ₹4.50 per equity share** for the financial year ended March 31, 2025. The record date for determining eligible shareholders has been set as Friday, August 1, 2025. Additionally, the board approved a proposal to seek shareholder approval via special resolution to raise up to **₹1,500 Crore** in a financial year through the issuance of debt securities, including non-convertible debentures (NCDs), on a private placement basis.
Kammavari Sangham will establish hospital infrastructure with a capacity of **110 beds in the Bengaluru South region**. This project is expected to commence operations in FY 2026-27.
Narayana Hrudayalaya Ltd. has received observation letters from BSE and NSE for its **Scheme of Arrangement with Meridian Medical Research & Hospital Ltd.**, marking progress in the amalgamation process, pending further approvals. The company continues to strengthen its market position through strategic partnerships and operational improvements.
Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya, stated, "The current financial year demonstrated strong performance across our units, both domestic and international; we are pleased to report the highest-ever revenues and profitability margins on both a quarterly and an annual basis at the consolidated level." He further added, "While our flagships continue to contribute significantly, our Southern Peripheral and North units have shown significant growth this year, and we hope to build on the momentum going forward. HCCI continues to contribute significantly, delivering record revenues on both a quarterly and annual basis."
As of March 31, 2025, the company's total borrowings, net of cash, bank balances, and current investments, stood at **₹533 Crore**. The net debt-to-equity ratio was at **0.15**, with foreign currency-denominated debt amounting to $86.8 million.
Narayana Hrudayalaya continues to maintain a strong financial position with controlled debt levels and demonstrates consistent performance across both domestic and international operations, positioning itself as a leading player in India's healthcare sector.
